ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0942

Evaluation of Ovarian Reserve Using Anti-Mullerian Hormone Levels in Adolescents with Systemic Rheumatic Disease Compared to Healthy Controls

Alexandra Theisen1, Kathleen Lane1, Jodi Skiles1, Amanda Saraf1, Stacey Tarvin2, Tamara Hannon1, Marcia Shew1 and Melissa Oliver1, 1Indiana University School of Medicine, Indianapolis, IN, 2Riley Hospital for Children at Indiana University Health, Indianapolis, IN

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Pediatric rheumatology, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Medical evidence suggests decreased ovarian reserve in women with rheumatic disease; however, studies in adolescents are lacking. Anti-Mullerian hormone (AMH) levels in serum are shown to be a reliable marker of ovarian reserve. This study investigated the effect of pediatric rheumatic diseases, specifically adolescents meeting classification criteria for systemic lupus erythematosus (SLE), ANCA-vasculitis (AAV), Takayasu arteritis (TA), juvenile dermatomyositis (JDM), and mixed connective tissue disease (MCTD) on ovarian reserve as reflected by AMH levels.

Methods: AMH levels were collected and analyzed by quantitative ELISA from SLE, JDM, MCTD, AAV, and TA post-menarchal adolescents aged 11-20y and from menstrual age-matched, healthy controls. Demographic, menstrual, and rheumatic disease-specific characteristics were also collected. SLE disease activity, measured by SLE Disease Activity Index (SLEDAI), was evaluated in SLE and MCTD adolescents at time of enrollment. These characteristics were compared between the groups using two-sample tests and Fisher’s exact tests as appropriate. Univariate linear regression models were used to test the association of specific rheumatic disease characteristics and disease activity on AMH levels in the diseased group.

Results: Median age of adolescents with rheumatic disease was 15.8 ± 2.5 years. Median age of healthy controls was 15.1 ± 2.5 years. Age of onset of menarche corrected for race and menstrual characteristics were not significantly different from healthy controls (Table 1). Adolescents with rheumatic disease had significantly reduced AMH levels compared to healthy controls (3.6 ± 2.4 ng/mL vs. 5.6 ± 3.3 ng/mL, p=0.0008) (Figure 1). Among adolescents with SLE and MCTD, increased SLEDAI was associated with reduced AMH levels (p=0.02). AMH levels among adolescents with SLE and adolescents with other rheumatic disease were not significantly different. Prednisone exposure and evidence of cardiac involvement was associated with reduced AMH levels, whereas renal involvement, antiphospholipid antibody positivity and cyclophosphamide exposure were not significantly associated with reduced AMH levels in the diseased group (Table 2).

Conclusion: Serum AMH levels were significantly reduced in adolescents with rheumatic disease compared to menstrual-age matched, healthy controls. In adolescents with SLE and MCTD, higher disease activity was associated with reduced AMH levels. These findings suggest rheumatic disease and disease activity may affect ovarian reserve. Pediatric rheumatologists should be aware of this finding when considering their patients’ reproductive health. This pilot study indicates further studies are needed to assess the effect of pediatric rheumatologic disease on ovarian reserve.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: A. Theisen, None; K. Lane, None; J. Skiles, None; A. Saraf, None; S. Tarvin, None; T. Hannon, Eli Lilly; M. Shew, None; M. Oliver, None.

To cite this abstract in AMA style:

Theisen A, Lane K, Skiles J, Saraf A, Tarvin S, Hannon T, Shew M, Oliver M. Evaluation of Ovarian Reserve Using Anti-Mullerian Hormone Levels in Adolescents with Systemic Rheumatic Disease Compared to Healthy Controls [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-ovarian-reserve-using-anti-mullerian-hormone-levels-in-adolescents-with-systemic-rheumatic-disease-compared-to-healthy-controls/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-ovarian-reserve-using-anti-mullerian-hormone-levels-in-adolescents-with-systemic-rheumatic-disease-compared-to-healthy-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology